Ligand Pharmaceuticals
LGND
266 hedge funds and large institutions have $2.37B invested in Ligand Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 60 increasing their positions, 130 reducing their positions, and 31 closing their positions.
10.52% more ownership
Funds ownership: 196.89% → 207.41% (+11%)
2% more capital invested
Capital invested by funds: $2.32B → $2.37B (+$45M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 31
3% less funds holding
Funds holding: 275 → 266 (-9)
46% less call options, than puts
Call options by funds: $75.6M | Put options by funds: $140M
54% less repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 130
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$26.9M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$18.1M |
| 3 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$8.69M |
| 4 |
William Blair Investment Management
Chicago,
Illinois
|
+$8.65M |
| 5 |
Morgan Stanley
New York
|
+$8.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$24.2M |
| 2 |
CTA
Carillon Tower Advisers
St. Petersburg,
Florida
|
-$22.3M |
| 3 |
Renaissance Technologies
New York
|
-$21.2M |
| 4 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
-$20.7M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$11.3M |
LGND Hedge Fund Activity: Q4 2019 in Review
266 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q4 2019, worth a combined $2.37B — up 1.9% from $2.32B a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of LGND and 30 opened new positions — a net loss of 1 holder — while 130 trimmed existing stakes and 60 added.
The largest buyer was Janus Henderson Group, adding an estimated $26.9M. The largest seller was Eagle Asset Management, cutting an estimated $24.2M.
- 266 institutional investors held Ligand Pharmaceuticals (LGND) as of Q4 2019, down from 275 in Q3 2019.
- Funds reported $2.37B of Ligand Pharmaceuticals stock for Q4 2019, up 1.9% quarter-over-quarter.
- 30 funds opened new Ligand Pharmaceuticals positions in Q4 2019 and 31 closed out, a net change of -1 holder.
- The largest Ligand Pharmaceuticals buyer in Q4 2019 was Janus Henderson Group, an estimated $26.9M added.
- The largest Ligand Pharmaceuticals seller in Q4 2019 was Eagle Asset Management, an estimated $24.2M sold.
Based on aggregated 13F filings for Q4 2019.